Lineage Cell Therapeutics, Inc. (LCTX)
1.025
+0.08
(+8.17%)
USD |
NYAM |
Oct 08, 16:00
1.025
0.00 (0.00%)
After-Hours: 20:00
Lineage Cell Therapeutics Gross Profit Margin (Quarterly) : 82.51% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 82.51% |
| March 31, 2026 | 89.10% |
| December 31, 2025 | 96.19% |
| September 30, 2025 | 95.03% |
| June 30, 2025 | 92.41% |
| March 31, 2025 | 86.68% |
| December 31, 2024 | 89.37% |
| September 30, 2024 | 95.26% |
| June 30, 2024 | 86.79% |
| March 31, 2024 | 81.09% |
| December 31, 2023 | 79.36% |
| September 30, 2023 | 72.31% |
| June 30, 2023 | 90.79% |
| March 31, 2023 | 87.85% |
| December 31, 2022 | 84.86% |
| September 30, 2022 | 86.22% |
| June 30, 2022 | 91.37% |
| March 31, 2022 | 93.16% |
| December 31, 2021 | 59.38% |
| September 30, 2021 | 46.23% |
| June 30, 2021 | 26.76% |
| March 31, 2021 | -35.84% |
| December 31, 2020 | -171.1% |
| September 30, 2020 | -61.11% |
| June 30, 2020 | -525.3% |
| Date | Value |
|---|---|
| March 31, 2020 | -384.3% |
| December 31, 2019 | -15.02% |
| September 30, 2019 | -299.5% |
| June 30, 2019 | -230.4% |
| March 31, 2019 | -359.2% |
| December 31, 2018 | -365.5% |
| September 30, 2018 | 9.47% |
| June 30, 2018 | 61.33% |
| March 31, 2018 | -38.66% |
| December 31, 2017 | 8.51% |
| September 30, 2017 | 47.69% |
| June 30, 2017 | -112.6% |
| March 31, 2017 | -124.4% |
| December 31, 2016 | 25.58% |
| September 30, 2016 | 36.69% |
| June 30, 2016 | -9.95% |
| March 31, 2016 | 5.07% |
| December 31, 2015 | -20.88% |
| September 30, 2015 | 12.84% |
| June 30, 2015 | 9.24% |
| March 31, 2015 | -45.58% |
| December 31, 2014 | -97.88% |
| September 30, 2014 | -57.05% |
| June 30, 2014 | -70.33% |
| March 31, 2014 | -64.71% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Agenus, Inc. | 98.50% |
| Amgen, Inc. | 72.08% |
| BioCryst Pharmaceuticals, Inc. | 98.01% |
| Imunon, Inc. | -- |
| Curis, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -71.74% |
| Return on Assets | -31.55% |
| Return on Invested Capital | -68.12% |
| Operating Margin (Quarterly) | -834.7% |
| Return on Net Operating Assets | -67.20% |